Advertisement

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study

  • Seung Hyup Hyun
  • Jae Seon Eo
  • Jeong Won Lee
  • Joon Young Choi
  • Kyung-Han Lee
  • Sae Jung Na
  • Il Ki Hong
  • Jin Kyoung Oh
  • Yong An Chung
  • Bong-Il Song
  • Tae-Sung Kim
  • Kyung Sik Kim
  • Dae Hyuk MoonEmail author
  • Mijin YunEmail author
Original Article

Abstract

Purpose

We evaluated the prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A hepatocellular carcinoma (HCC) who had received curative treatment or transarterial chemoembolization (TACE).

Methods

Between 2009 and 2010, 317 patients diagnosed with HCC at seven hospitals were enrolled. Among these, 195 patients underwent curative treatments including resection, liver transplantation, and radiofrequency ablation. TACE was performed in 122 patients. The tumor-to-normal liver standardized uptake value ratio (TLR) of the primary tumor was measured using pretreatment FDG PET/CT. The prognostic significance of TLR and other clinical variables was assessed using Cox regression models. Differences in the overall survival (OS) associated with TLR or other significant clinical factors were examined using the Kaplan-Meier method.

Results

Over a median follow-up period of 46 months, 77 patients died from cancer. In the curative cohort, higher TLR (≥2) was significantly associated with death (hazard ratio [HR] = 2.68; 95 % CI, 1.16–6.15; P = 0.020) in multivariable analysis. Patients with a higher TLR had significantly worse OS than patients with a lower TLR (5-year overall survival, 61 % vs. 79.4 %; P = 0.006). In the TACE cohort, the Model for End-Stage Liver Disease (MELD) score (≥8) was a significant independent prognostic factor for OS (HR = 3.34; 95 % CI, 1.49–7.48; P = 0.003), whereas TLR was not associated with OS. The Kaplan-Meier curves showed significantly poorer OS in patients with higher MELD scores (≥8) than in those with lower MELD scores (5-year survival rate, 33.1 % vs. 79.6 %; P < 0.001).

Conclusions

Pretreatment TLR measured using FDG PET/CT was an independent prognostic factor for OS in patients with BCLC stage 0 or A HCC undergoing curative treatment. In contrast, underlying liver function appeared to be important in predicting the prognosis of patients undergoing TACE.

Keywords

FDG PET/CT Hepatocellular carcinoma Standardized uptake value Prognosis Multicenter trial 

Notes

Compliance with ethical standards

Funding

This research was supported by the Korean Society of Nuclear Medicine Clinical Trial Network (KSNM CTN) working group funded by the Korean Society of Nuclear Medicine (KSNM-CTN-2014-02-1) and Korea University (grant no. K1422321).

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

Written informed consent was waived.

Supplementary material

259_2016_3348_MOESM1_ESM.docx (21 kb)
Table S1 (DOCX 21 kb)
259_2016_3348_MOESM2_ESM.docx (20 kb)
Table S2 (DOCX 20 kb)

References

  1. 1.
    European Association for The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRefGoogle Scholar
  2. 2.
    Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35:2155–66.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Eo JS, Paeng JC, Lee DS. Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. World J Gastroenterol. 2014;20:5375–88.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912–21.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009;50:682–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Ahn SG, Jeon TJ, Lee SD, Kim SH, Cho HJ, Yun M, et al. A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. Eur J Surg Oncol. 2013;39:964–73.CrossRefPubMedGoogle Scholar
  8. 8.
    Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, et al. The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg. 2011;15:2044–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Yamanaka K, et al. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:156–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Kornberg A, Freesmeyer M, Barthel E, Jandt K, Katenkamp K, Steenbeck J, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009;9:592–600.CrossRefPubMedGoogle Scholar
  11. 11.
    Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Pant V, Sen IB, Soin AS. Role of 18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun. 2013;34:749–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73–85.CrossRefGoogle Scholar
  15. 15.
    Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an eastern point of view. Liver Transpl. 2004;10:S3–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Park SK, Jung YK, Chung DH, Kim KK, Park YH, Lee JN, et al. Factors influencing hepatocellular carcinoma prognosis after hepatectomy: a single-center experience. Korean J Intern Med. 2013;28:428–38.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014;4:736–44.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. Clin Radiol. 2015;70:128–37.CrossRefPubMedGoogle Scholar
  19. 19.
    Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging. 2012;46:102–10.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Song MJ, Bae SH, Lee SW, Song d S, Kim HY, Yoo lR, et al. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee JW, Yun M, Cho A, Han KH, Kim d Y, Lee SM, et al. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Lin WY, Tsai SC, Hung GU. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun. 2005;26:315–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Seung Hyup Hyun
    • 1
  • Jae Seon Eo
    • 2
  • Jeong Won Lee
    • 3
  • Joon Young Choi
    • 1
  • Kyung-Han Lee
    • 1
  • Sae Jung Na
    • 4
  • Il Ki Hong
    • 5
  • Jin Kyoung Oh
    • 6
  • Yong An Chung
    • 6
  • Bong-Il Song
    • 7
  • Tae-Sung Kim
    • 8
  • Kyung Sik Kim
    • 9
  • Dae Hyuk Moon
    • 10
    Email author
  • Mijin Yun
    • 11
    Email author
  1. 1.Department of Nuclear Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Department of Nuclear MedicineKorea University Guro Hospital, Korea University College of MedicineSeoulRepublic of Korea
  3. 3.Department of Nuclear Medicine, International St. Mary’s HospitalCatholic Kwandong University College of MedicineIncheonRepublic of Korea
  4. 4.Department of Nuclear Medicine, Uijeongbu St. Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea
  5. 5.Department of Nuclear MedicineKyung Hee University Hospital, School of Medicine, Kyung Hee UniversitySeoulRepublic of Korea
  6. 6.Department of Nuclear Medicine, Incheon St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaIncheonRepublic of Korea
  7. 7.Department of Nuclear Medicine, Dongsan Medical CenterKeimyung University School of MedicineDaeguRepublic of Korea
  8. 8.Department of Nuclear MedicineResearch Institute and Hospital, National Cancer CenterGoyangRepublic of Korea
  9. 9.Department of SurgeryYonsei University College of MedicineSeoulRepublic of Korea
  10. 10.Department of Nuclear Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulRepublic of Korea
  11. 11.Department of Nuclear Medicine, Severance HospitalYonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations